- Molecular NameCyclobenzaprine
- SynonymCyclobenzaprine HCL
- Weight275.395
- Drugbank_IDDB00924
- ACS_NO303-53-7
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)4.68
- pka8.47
- LogD (pH=7, predicted)2.89
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.92
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.04
- No.of HBond Donors0
- No.of HBond Acceptors1
- No.of Rotatable Bonds3
- TPSA3.24
- StatusFDA approved
- AdministrationPO (Per Oral)
- PharmacologyA drug that works in the central nervous system by altering the signals from the brain that cause muscles to tighten.
- Absorption_valueN/A
- Absorption (description)Irregularly absorbed after oral administration
- Caco_2N/A
- Bioavailability55.0
- Protein binding93.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmExtensively metabolised. The major metabolites are a glucuronide conjugate and 10,11-dihydroxynortriptyline; monodesmethylcyclobenzaprine is a minor metabolite.
- Half life1~3 days
- ExcretionAbout 50% of an oral dose is excreted in the urine in 5 days, with less than 1% as unchanged drug. About 14% of a dose is eliminated in the faeces.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySigns of overdose include agitation, coma, confusion, congestive heart failure, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high or low temperature, increased heartbeats, irregular heart rhythms, muscle stiffness, overactive reflexes, severe low blood pressure, stupor, and vomiting.
- LD50 (rat)425 mg/kg
- LD50 (mouse)338 mg/kg